Amendment to Promissory Notes, dated January 9, 2025, between Bellevue Life Sciences Acquisition Corp. and Bellevue Global Life Sciences Investors, LLC

Exhibit 10.1

AMENDMENT TO PROMISSORY NOTES

Reference is made to those certain promissory notes listed on Exhibit A hereto (each, a “Note” and, collectively, the “Notes”), between Bellevue Life Sciences Acquisition Corp., a Delaware corporation, and Bellevue Global Life Sciences Investors, LLC, a Delaware limited liability company.

1. Extension of the Maturity Date. The parties hereto agree that Section 1 of each Note shall be amended and restated in its entirety as follows: “The Principal balance of this Note shall be payable by the Maker on the earlier of: (i) September 30, 2025 and (ii) the date on which Maker consummates an initial business combination (the “Maturity Date”). The principal balance may be prepaid at any time. Under no circumstances shall any individual, including but not limited to any officer, director, employee or stockholder of the Maker be obligated personally for any obligations or liabilities of the Maker hereunder.”

2. Binding Effect. Except as amended pursuant to paragraph 1 above, the Notes shall remain in full force and effect in accordance with their terms and are hereby ratified and confirmed by each of the parties hereto.

3. Counterparts. This amendment may be executed in one or more counterparts (including by electronic transmission), each of which will be deemed to be an original copy of this amendment and all of which, when taken together, will be deemed to constitute one and the same agreement.

[Signature page follows]

IN WITNESS WHEREOF, the parties hereto have caused this amendment to be duly executed as of the latest date set forth below.

[Signature page to Promissory Note Amendment]

Exhibit A

Promissory Notes